This site is intended for Healthcare Professionals only.

Pharmacists urged to promote Oxford vaccine safety study among patients

Date:

Share post:

The PSNC has asked community pharmacy teams to encourage their patients who have had Oxford/AstraZeneca Covid-19 vaccine to participate in a safety study about the vaccine.

The safety study on the vaccine allows the experts to quickly recognise any side effects and to act upon it, the Pharmaceutical Services Negotiating Committee (PSNC) said.

“Pharmacy teams are encouraged to display the poster about the study in their pharmacy and then highlight this to patients who they know have received the Oxford/AstraZeneca vaccine and encourage them to participate,” the pharmacy negotiator said.

“Patients can sign up within 28 days of receiving the vaccination or they can register their interest in taking part in the study before they are vaccinated. Patients can register by visiting goto.dsru.org/covid or by calling 0800 619 6222,” it added.

Pharmacy team members can also sign up for the study themselves if they have had the vaccine within the last 28 days or they can register their interest in taking part in the study before they are vaccinated.

The Drug Safety Research Unit (DSRU) in Southampton, an Associate Department of the School of Pharmacy and Biomedical Sciences, University of Portsmouth, is monitoring the safety of the vaccine by proactively collecting near ‘real-time’ data from patients receiving the vaccine.

All participants will be asked basic information about the vaccine and their health. They will then receive questionnaires at intervals for up to 18 months – the anticipated length of the study.

A random sample of participants will also be asked questions regarding their quality of life in the months following their vaccination.

The DSRU research team will collate and study information provided by participants to explore whether any side effects seen in the study population are likely to be linked to the vaccine.

The team will provide monthly updates to the pharmaceutical manufacturer and to the regulator, Medicines and Healthcare products Regulatory Authority.

It will also provide a summary of the study results on its website and will publish results in scientific journals.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Pharmacy First service: Two Numark members share their experiences

Lack of cooperation from GP surgeries stalling the uptake of Pharmacy First service in some areas  The nationwide implementation...

A 5 year analysis: Rural pharmacy closures outpace openings

Findings call for more attention to rural pharmacy as only 8 opened in 2023 across the UK  The Department...

33 % rise in women seeking perinatal mental health support since 2022

One in five new and expectant mothers may be affected by perinatal mental health conditions In a significant uptick...

UK GDP Association Delivers Affordable GDP Consultancy for Small Businesses

“We want to help plug the gap where current consultancies fail these smaller businesses, and ultimately benefit UK...